Physician profile
Stephen L Nelson
NPI 1356362008
$100,562.40
in general payments reported to CMS, 2019-2025
38 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $11K · 2021: $12K · 2022: $15K · 2023: $19K · 2024: $19K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $49K · Food and Beverage: $2,659 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $48,900.00 |
| Food and Beverage | $2,658.86 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $48,900.00 | 2023-2025 | |
| Csl Behring | $47,250.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,085.34 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $332.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $324.77 | 2019-2025 | Evenity, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $322.04 | 2019-2022 | |
| Abbvie INC. | $291.55 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $226.32 | 2023-2025 | Rexulti, Abilify Maintena |
| Novo Nordisk INC | $209.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $168.27 | 2021-2024 | Austedo Xr |
| Lilly USA, LLC | $159.56 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Merck Sharp & Dohme LLC | $121.79 | 2020-2024 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $115.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $114.34 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.44 | 2019-2025 | Trintellix |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.